JNJ · Johnson & Johnson
$243.042026-05-17Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Pharmaceuticals
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$184
-24.4% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($166 · $402) Analysts Range ($190 · $265) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $78.7B | — | 29.2% | 8.3% | $21.1B | −$3.0B | $18.1B | 3.4% | — | 17.4% | $121.0B | $8.56 | — |
| 2022.Q4 | $80.0B | 1.6% | 28.9% | 15.6% | $19.5B | −$21.1B | −$1.6B | 5.4% | — | 15.0% | $138.5B | $7.36 | — |
| 2023.Q4 | $85.2B | 6.5% | 30.2% | 11.5% | $22.7B | $3.2B | $26.0B | 5.3% | — | 17.4% | $122.5B | $14.41 | — |
| 2024.Q4 | $88.8B | 4.3% | 27.4% | 15.7% | $20.5B | −$14.6B | $5.9B | 5.1% | — | 15.8% | $137.7B | $5.77 | — |
| 2025.Q4 | $94.2B | 6.0% | 29.8% | 17.7% | $23.1B | −$30.1B | −$7.0B | 5.6% | — | 15.8% | $155.4B | $10.99 | 21.1 |
| italics below = DCF projection · 10yr Rev CAGR: 5.6% |
| 2026.Q4 | $100.6B | +6.8% | 30.0% | 18.0% | $24.8B | −$18.5B | $6.3B | 5.9% | $6.0B | 15.0% | $173.8B | $9.24 | 26.3 |
| 2027.Q4 | $106.7B | +6.0% | 30.5% | 18.2% | $26.6B | −$14.0B | $12.7B | 6.1% | $11.3B | 14.7% | $187.8B | $9.94 | 24.5 |
| 2028.Q4 | $113.2B | +6.1% | 30.9% | 18.4% | $28.6B | −$12.4B | $16.2B | 6.4% | $13.5B | 14.7% | $200.2B | $10.67 | 22.8 |
| 2029.Q4 | $119.9B | +6.0% | 32.8% | 18.6% | $32.0B | −$16.9B | $15.1B | 6.7% | $11.8B | 15.3% | $217.2B | $11.93 | 20.4 |
| 2030.Q4 | $127.4B | +6.2% | 32.8% | 18.9% | $33.9B | −$18.0B | $15.9B | 7.0% | $11.6B | 15.0% | $235.2B | $12.64 | 19.2 |
|
| Term. Yr+ | $168.9B | 4.1% | 29.9% | 20.0% | $40.4B | −$12.6B | $27.7B | 8.6% | $310.5B | 13.1% | — | — | — |
Active scenario IV: $184 (-24.4% vs market)